Adaptimmune at American Society of Hematology (ASH) Annual Meeting Confirm NY-ESO SPEAR T-cell Efficacy in Multiple Myeloma Pilot Study

Monday, December 11, 2017 5:30 p.m. ET  
Title
Adaptimmune at American Society of Hematology (ASH) Annual Meeting Confirm NY-ESO SPEAR T-cell Efficacy in Multiple Myeloma Pilot Study
Date / Time
12/11/17 5:30 p.m. ET
Location
Bldg. B, Level 2, B206 (Georgia World Congress Center)
  
Description

Oral Presentation 845: Phase I/IIa Study of Genetically Engineered NY-ESO-1 SPEAR T-Cells Administered Following Autologous Stem Cell Transplant in HLA-a*02+ Patients with Advanced Multiple Myeloma: Long Term Follow‑up (NCT01352286)

Session: 703. Adoptive Immunotherapy: Gene Engineered T cells for Hematologic Malignancies

Time: Monday, December 11, 2017: 5:30 PM (EST)

Location: Bldg. B, Level 2, B206 (Georgia World Congress Center)

Result highlights from the abstract include:

  • Overall response rate (ORR) at day 100 was 76% (1 stringent complete response [sCR]; 12 very good partial response [VGPR]; 6 partial response [PR])
  • At year 1, 13 patients were progression free (52%) of which 11 were responders (1 sCR; 1 CR; 8 VGPR; 1 PR)
  • Three patients remain disease progression-free at 39, 56, and 61 months post T-cell infusion
  • Median progression free survival (PFS) was ~13 months (range 3-61 months)
  • Eleven of 25 patients (44%) are alive, and median survival was ~35 months (range 6-68 months)
  • Autologous GvHD (24%) was reported in 6 patients (3 G3, 3 ≤G2); all resolved with corticosteroids and supportive therapy
  • No fatal adverse events have been reported